A Single Center, Open-label, Two Cohorts, Fixed Sequence Trial, Investigating the Influence of HRS9531 Injection on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin in Healthy Subjects.

The article discusses a clinical trial, NCT06723691, conducted by Fujian Shengdi Pharmaceutical Co., Ltd., to evaluate the influence of HRS9531 injection on gastric emptying and the pharmacokinetics of metformin, atorvastatin, warfarin, and digoxin in healthy subjects. The trial aims to assess various outcome measures related to the plasma concentration-time curves of the drugs involved. The study is still in the recruitment phase, with a planned completion date of May 31, 2025, and includes specific eligibility criteria for participants. [Extracted from the article]